1123979--2/12/2009--SENOMYX_INC

related topics
{product, candidate, development}
{property, intellectual, protect}
{provision, law, control}
{control, financial, internal}
{stock, price, operating}
{stock, price, share}
{cost, operation, labor}
{acquisition, growth, future}
{condition, economic, financial}
{product, market, service}
{product, liability, claim}
{cost, regulation, environmental}
{personnel, key, retain}
Risks Related To Our Business We are dependent on our product discovery and development collaborators for all of our revenue and we are dependent on our current and any future product discovery and development collaborators to develop and commercialize any flavor ingredients we may discover. Our business and operating results may be adversely affected by unfavorable economic and market conditions. We may not be able to negotiate additional collaboration agreements having terms satisfactory to us or at all. We may not be successful in developing flavor ingredients useful for formulation into products. If we or our collaborators are unable to obtain and maintain the GRAS determination or other regulatory approval required before certain of our flavor ingredients can be incorporated into products that are sold, we would be unable to commercialize our flavor ingredients and our business would be adversely affected. If we or our collaborators are unable to obtain and maintain the regulatory approval required before any high potency sweeteners can be incorporated into products that are sold, we would be unable to commercialize our high potency sweeteners and our business would be adversely affected. Even if we or our collaborators receive regulatory approval and incorporate our flavor ingredients into products, those products may never be commercially successful. We have a history of operating losses and we may not achieve or maintain profitability. We expect that our results of operations will fluctuate from period to period, and this fluctuation could cause our stock price to decline. We may need to obtain additional capital to fund our operations. If we lose our key personnel or are unable to attract and retain qualified personnel, it could adversely affect our business. We may encounter difficulties managing our growth, which could adversely affect our business. We will rely on third parties to manufacture our flavor ingredients on a commercial scale. If we acquire products, technologies or other businesses, we will incur a variety of costs, may have integration difficulties and may experience numerous other risks that could adversely affect our business. Risks Related To Our Industry Our ability to compete in the flavor ingredient market may decline if we do not adequately protect our proprietary technologies. Many of the patent applications we and our licensors have filed have not yet been substantively examined and may not result in patents being issued. Disputes concerning the infringement or misappropriation of our proprietary rights or the proprietary rights of others could be time consuming and extremely costly and could delay our research and development efforts. If we are unable to protect our trade secrets and other proprietary information, we could lose any competitive advantage we may have, which could adversely affect our business. Many potential competitors, including those who have greater resources and experience than we do, may develop products or technologies that make ours obsolete or noncompetitive. We may be sued for product liability and exposed to other product safety-related risks, which could adversely affect our business and harm our reputation. We use hazardous materials. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly. Risks Related To Our Common Stock The price of our common stock is volatile. Anti-takeover provisions in our charter documents and under Delaware law may make an acquisition of us more complicated and the removal and replacement of our directors and management more difficult. Our shareholder rights plan may hinder or prevent change of control transactions. We have never paid cash dividends on our capital stock and we do not anticipate paying dividends in the foreseeable future.

Full 10-K form ▸

related documents
1123979--2/4/2010--SENOMYX_INC
1033025--3/17/2006--PRAECIS_PHARMACEUTICALS_INC
1066833--3/15/2006--DOV_PHARMACEUTICAL_INC
805326--3/25/2010--EMISPHERE_TECHNOLOGIES_INC
805326--3/16/2009--EMISPHERE_TECHNOLOGIES_INC
1162192--3/31/2009--AVALON_PHARMACEUTICALS_INC
805326--3/6/2007--EMISPHERE_TECHNOLOGIES_INC
819050--2/23/2007--VICAL_INC
1005201--3/16/2006--DEPOMED_INC
1123979--2/23/2007--SENOMYX_INC
1123979--2/14/2008--SENOMYX_INC
1029142--3/16/2006--DYNAVAX_TECHNOLOGIES_CORP
1029142--3/16/2007--DYNAVAX_TECHNOLOGIES_CORP
819050--3/10/2006--VICAL_INC
895051--3/13/2009--ENTREMED_INC
819050--3/3/2009--VICAL_INC
819050--2/25/2010--VICAL_INC
819050--3/3/2008--VICAL_INC
877902--3/8/2006--NEOSE_TECHNOLOGIES_INC
1140028--3/16/2006--Hana_Biosciences_Inc
887151--3/13/2006--ORTHOLOGIC_CORP
818033--3/31/2006--AP_PHARMA_INC_/DE/
1099215--7/31/2007--PROTALEX_INC
730272--6/9/2006--REPLIGEN_CORP
907562--3/4/2009--DYAX_CORP
882796--3/9/2010--BIOCRYST_PHARMACEUTICALS_INC
64978--3/30/2010--MERCK_SHARP_&_DOHME_CORP.
824068--3/14/2008--ATS_MEDICAL_INC
1171012--3/12/2010--Uni-Pixel
1171012--3/6/2009--Uni-Pixel